Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV
- 3 April 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 220 (4), 635-642
- https://doi.org/10.1093/infdis/jiz144
Abstract
Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is associated with viral suppression in persons living with HIV (PLWH) taking tenofovir disoproxil fumarate (TDF). However, its value as a predictor of future viremia remained unknown. Blood for plasma viral load (VL) and TFV-DP in DBS were collected (up to 3 visits within 48 weeks) in PLWH on TDF. TFV-DP cut points were selected using logistic prediction models maximizing the area under the receiver operation characteristic curve, and estimated adjusted odds ratio (aOR) of future viremia (≥20 copies/mL) were compared to the highest TFV-DP category. Among all 451 participants in the analysis, aOR of future viremia for participants with TFV-DP P < .0001) and 2.1 (95% CI, 1.3–3.3; P = .002) versus ≥1650 fmol/punch, respectively. These remained significant for participants who were virologically suppressed at the time of the study visit (4.2; 95% CI, 1.5–12.0; P = .007 and 2.2; 95% CI, 1.2–4.0; P = .01). TFV-DP in DBS predicts future viremia in PLWH on TDF, even in those who are virologically suppressed. This highlights the utility of this biomarker to inform about adherence beyond VL. Clinical Trials Registration. NCT02012621.Keywords
Funding Information
- National Institutes of Health (K23 AI104315, R01 AI122298)
This publication has 38 references indexed in Scilit:
- HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral TreatmentThe Journal of Infectious Diseases, 2010
- Antiretroviral Adherence and Development of Drug Resistance Are the Strongest Predictors of Genital HIV‐1 Shedding among Women Initiating TreatmentThe Journal of Infectious Diseases, 2010
- The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral TherapyPLOS ONE, 2009
- Antiretroviral medication adherence and the development of class-specific antiretroviral resistanceAIDS, 2009
- Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-RitonavirAntimicrobial Agents and Chemotherapy, 2009
- Not All Missed Doses Are the Same: Sustained NNRTI Treatment Interruptions Predict HIV Rebound at Low-to-Moderate Adherence LevelsPLOS ONE, 2008
- Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral TherapyPLoS Medicine, 2008
- Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapiesAIDS, 2007
- Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West AfricaAIDS, 2007
- Self-Report Measures of Antiretroviral Therapy Adherence: A Review with Recommendations for HIV Research and Clinical ManagementAIDS and Behavior, 2006